Putting Unexpected Safety Findings for Overactive Bladder Treatments in Context

By
Sudeep S. Gill
November 6, 2026

Jama Network Open

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Putting Unexpected Safety Findings for Overactive Bladder Treatments in Context
Key Mechanisms	The article discusses the cholinergic hypothesis as background to concern about anticholinergic medications and notes that OAB may represent a prodrome of neurodegenerative or cerebrovascular processes, potentially contributing to confounding by indication.
Target Population	Patients or participants described in the source article.
Care Setting	Retrospective analysis of Epic Cosmos electronic health records collected from 2012 through 2025.

Key Highlights

The retrospective cohort included 830,393 adults treated for OAB.
Dementia incidence was not statistically significantly lower with β3 adrenergic agonists than with anticholinergic medications.
After confounder balancing, regular anticholinergic use was associated with a modestly lower hazard; β3 agonists showed the highest 10-year incidence.
Longer exposure to anticholinergic medications was not associated with increased dementia risk in the exploratory duration-response analysis.
The authors note that channeling bias, residual confounding, and confounding by indication could explain the findings.

Guideline-Based Recommendations

Diagnosis

Management

The article reports that current guidelines advise caution when using anticholinergic medication for OAB.
The article describes β3 agonists as a reasonable option amid concern about potential adverse effects of strongly anticholinergic medications.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Compared with anticholinergic medications, β3 agonists were not statistically significantly associated with lower dementia incidence and were not protective relative to anticholinergic medications, according to the study authors.

Clinical Best Practices

The article reports that current guidelines advise caution with anticholinergic medications for OAB.
The article describes β3 agonists as a reasonable option amid concern about potential adverse effects linked to strongly anticholinergic medications.
Interpret the cohort findings cautiously: the authors identify possible channeling bias, residual confounding, and confounding by indication.